Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 8/2006

01-08-2006 | Original Paper

Effects of Saccharomyces boulardii on Intestinal Mucosa

Authors: Jean-Paul Buts, Nadine De Keyser

Published in: Digestive Diseases and Sciences | Issue 8/2006

Login to get access

Abstract

Saccharomyces boulardii (S. boulardii) is a non-pathogenic biotherapeutic agent, widely prescribed in a lyophilized form in many countries over the world. S. boulardii acts as a shuttle liberating effective enzymes, proteins and trophic factors during its intestinal transit that improve host immune defenses, digestion, and absorption of nutrients. In addition, S. boulardii secretes during its intestinal transit polyamines, mainly spermine and spermidine that regulate gene expression and protein synthesis. In this review, we will focus on the interactions of the yeast with the host intestinal mucosa.
Literature
1.
McFarland LV, Bernasconi P (1993) Saccharomyces boulardii: A review of an innovative biotherapeutic agent. Microbiol Ecol Health Dis 6:151–171CrossRef
2.
Elmer GW, Surawicz CM, McFarland LV (1996) Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal secretions. JAMA 275:870–876
3.
Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, Van Belle G (1989) Prevention of antibiotic associated diarrhoea by Saccharomyces boulardii: A prospective study. Gastroenterology 96:981–988PubMed
4.
McFarland LV, Surawicz CM, Greenberg RN, et al. (1995) Prevention of ß–lactam associated diarrhoea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90:439–448PubMed
5.
McFarland LV, Surawicz CM, Greenberg RN, et al. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271:1913–1918PubMedCrossRef
6.
Surawicz CM, McFarland LV, Greenberg R, et al. (2000) The search for a better treatment for Clostridium difficile disease: Use of high-dose Vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31:1012–1017PubMedCrossRef
7.
Buts JP, Corthier G, Delmée M (1993) Saccharomyces boulardii for Clostridium difficile-associated enterocolopathies in infants. J Pediatr Gastroenterol Nutr 16:1497–1504
8.
Höchter W, Chase D, Hegenhoff G (1990) Saccharomyces boulardii in treatment of acute adult diarrhoea. Efficacy and tolerance of treatment. Münch Med Wochen 132:188–192
9.
Cetina-Sauri G, Sierra Basto G (1994) Evaluation thérapeutique de Saccharomyces boulardii chez des enfants souffrant de diarrhée aiguë. Ann Pediatr 41:397–400
10.
Kollaritsch H, Holst H, Grobara P, et al. (1993) Prophylaxe der Reisediarrhoë mith Saccharomyces boulardii. Forst Chr Med 111:152–156
11.
Buts JP (2004) Exemple d’un médicament probiotique Saccharomyces boulardii lyophylisé. In Rambaud JC, Buts JP, Corthier G, Fourié B (eds) Flore microbienne intestinale: Physiologie et pathologie digestives. John Libbey Eurotext, Montrouge, France, pp 221–244
12.
Bleichner G, Bléhaut H, Mentec H, Moyse D (1997) Sacchromyces boulardii prevents diarrhoea in critically ill tube-fed patients. A multicenter, randomized, double-blind–placebo-controlled trial. Intensive Care Med 23:517–523PubMedCrossRef
13.
Saint-Marc T, Bléhaut H, Musial C, Touraine JL (1991) Efficacité de Saccharomyces boulardii dans le traitement des diarrhées du SIDA. Am Med Int 142:64–65
14.
Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000) Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45:1462–1464PubMedCrossRef
15.
Guslandi M, Giollo P, Testoni PA (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15:697–698PubMedCrossRef
16.
Hennequin C, Thierry A, Richard GF, et al. (2001) Microsatellite typing as a new tool for identification of Saccharomyces cerevisiae strains. J Clin Microbiol 39:551–559PubMedCrossRef
17.
Maillée M, Van Nguyen P, Bertout S, Vaillant C, Bastide JM (2001) Genotypic study of Saccharomyces boulardii compared to the Saccharomyces sensu stricto complex species. J Mycol Med 11:19–25
18.
Bergogne-Berezin E (1995) Impact écologique de l’anti-biothérapie. Place des micro-organismes de substitution dans le contrôle des diarrhées et colites associées aux antibiotiques. Press Méd 24:145–156
19.
Buts JP (1999) Mechanisms of action of biotherapeutic agents. In Elmer GW, McFarland LV, Surawicz CM (eds) Biotherapeutic agents and infectious disease. Humana Pres, Totowa, NJ, pp 27–46
20.
Bléhaut H, Massot J, Elmer GW, Levy RM (1989) Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Dispos 10:353–364PubMedCrossRef
21.
Pothoulakis C, Kelly CP, Joshi MA, et al. (1993) Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104:1108–1115PubMed
22.
Castagliulo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C (1999) Saccharomyces boulardii protease mediates Clostridium difficile toxin A ad B effects in human colonic mucosa. Infect Immun 67:302–307
23.
Czerucka D, Roux J, Rampal P (1994) Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology 106:65–72PubMed
24.
Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P (2000) Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli infected T84 cells. Infect Immun 68:5998–6004PubMedCrossRef
25.
Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P (2001) Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection. Infect Imm 69:1298–1305CrossRef
26.
Czerucka D, Rampal P (2002) Experimental effects of Saccharomyces on diarrhoeal pathogens. Microbes Infect 4:733–739PubMedCrossRef
27.
Buts JP, Bernasconi P, Van Craynest MP, Maldague P, De Meyer R (1986) Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20:192–196PubMedCrossRef
28.
Jahn HU, Ullrick R, Schneider, et al. (1996) Immunology and tropical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. Digestion 57:95–104PubMedCrossRef
29.
Harms HK, Bertele-Harms RM, Bruer-Kleis D (1987) Enzyme substitution therapy with the yeast Saccharomyces cerevisiae in congenital sucrase isomaltase deficiency. N Engl J Med 316:1306–1309PubMedCrossRef
30.
Buts JP, DeKeyser N, Stilmant C, Sokal EM, Marandi S (2002) Saccharomyces boulardii enhances N-terminal peptide hydrolysis in suckling rat small intestine by endoluminal release of a zinc-binding metalloprotease. Pediatr Res 51:528–534PubMedCrossRef
31.
Buts JP, DeKeyser N, Marandi S, Hermans D, Chae YHE, Lambotte L, Chanteux H, Tulkens PM (1999) Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gut 45:89–96PubMedCrossRef
32.
Marandi S, De Keyser N, Hermans D, Chae YHE, Lambotte L, Buts JP (1999) Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats. Gastroenterology 116:G2382
33.
Zaouche A, Loukil C, de la Gausie P, et al. (2000) Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation and intestinal adaptation after small bowel resection in rats. Scand J Gastroenterol 35:160–165PubMedCrossRef
34.
Buts JP, Bernasconi P, Vaerman JP, Dive C (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci 35:251–256PubMedCrossRef
35.
Qamar A, Aboudola S, Warny M, Michetti P, Pothoulakis C, LaMont JT, Kelly CP (2001) Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Imm 69:2762–2765CrossRef
36.
37.
Pegg AE, McCamm PP (1982) Polyamine metabolism and function. Am J Physiol 243:C212–C221PubMed
38.
Pegg AE (1986) Recent advances in the biochemistry of polyamines in eukaryotes. Biochem J 243:249–262
39.
Buts JP (1996) Polyamines in milk. Ann Nestlé 54:18–104
40.
Wang JY, Viar MJ, McCormack SA, Johnson LR (1992) Effect of putrescine on S-adenosylmethionine decarboxylase in a small intestinal crypt cell line. Am J Physiol 263:G494–G501PubMed
41.
Buts JP, Theys S, De Keyser N, Dive C (1989) Changes in serum and intestinal diamine oxidase (DAO) activity after proximal enterectomy in rats. Correlation of DAO activity with mucosal mass parameters. Dig Dis Sci 34:1393–1398
42.
Pegg AE, Hibasami H, Matsui I, Bethell DR (1980) Formation and interconversion of putrescine and spermidine in mammalian cells. Adv Enzyme Regul 19:427–451PubMedCrossRef
43.
Panagiotidis CA, Artandi S, Calame K, Silvertein SJ (1995) Polyamines after sequence specific DNA–protein interactions. Nucleic Acid Res 23:1800–1809PubMedCrossRef
44.
Hampel KJ, Crosson P, Lee JS (1991) Polyamines favor DNA triplex formation at neutral pH. Biochemistry 30:4455–4459PubMedCrossRef
45.
Person L, Holm I, Heby O (1998) Regulation of ornithine decarboxylase mRNA translation by polyamines. J Biol Chem 263:3528–3533
46.
Kahana C, Nathans D (1985) Translational regulation of mammalian ornithine decarboxylase by polyamines. J Biol Chem 260:15390–15393PubMed
47.
Buts JP, De Keyser N, De Raedemaeker L (1994) Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 36:522–527PubMedCrossRef
48.
Buts JP, De Keyser N, Kolanowski J (1993) Maturation of villus and crypt cell functions in rat small intestine: Role of dietary polyamines. Dig Dis Sci 38:1091–1098PubMedCrossRef
49.
Miret JJ, Solari AJ, Barderi PA, Goldemberg SH (1992) Polyamines and cell wall organisation in Saccharomyces cerevisiae. Yeast 8:1033–1041PubMedCrossRef
50.
Buts JP, De Keyser N, De Raedemaeker L (1995) Polyamine profiles in human milk, infant, artificial formulas and semi-elemental diets. J Pediatr Gastroenterol Nutr 21:44–49PubMedCrossRef
51.
Kelly D, King TP, Brown DS, McFadyen M (1991) Polyamine profiles of porcine milk and of intestinal tissue of pigs during suckling. Reprod Nutr Dev 31:73–80PubMedCrossRef
52.
Bardocz S, Brown DS, Garant G, Pusztai A (1990) Luminal and basolateral polyamine uptake by rat small intestine stimulated to grow by phaseolus vulgaris pectin photohaemagglutinin in vivo. Biochem Biophys Acta 1034:46–52PubMed
53.
Kumagaï J, Jain R, Johnson LR (1989) Characteristics of spermidine uptake by isolated rat enterocytes. Am J Physiol 256:G905–G910PubMed
54.
Kobayashi M, Iseki K, Saitoh H, Miyazaki K (1992) Uptake characteristics of polyamines into rat intestinal brush border membrane. Biochem Biophys Acta 1105:177–183PubMedCrossRef
55.
Dufour C, Dandrifosse G, Forget P, et al. (1988) Spermine and spermidine induce intestinal maturation in the rat. Gastroenterology 95:112–116PubMed
56.
Bardocz S, Duguid TJ, Brown DS (1995) The importance of dietary polyamines in cell regeneration and growth. Br J Nutr 73:819–828PubMedCrossRef
57.
Osborne DL, Seifel ER (1989) Microflora-derived polyamines modulate obstruction-induced colonic mucosal hypertrophy. Am J Physiol 256:G1049–G1057PubMed
58.
Girard P, Pansart Y, Lorette I, Gillardin JM (2003) Dose-response relationship and mechanism of action of Saccharomyces boulardii in castor-oil-induced diarrhoea in rats. Dig Dis Sci 48:770–774PubMedCrossRef
59.
Schneider SM, Girard-Pipau F, Filippi J, Hebuterne X, Krab K, Nano JL, Piche T, Rampal P (2002) Effects of Saccharomyces boulardii on the intestinal flora of patients on long-term enteral nutrition. Gastroenterology 122:A459 (abstract)
Metadata
Title
Effects of Saccharomyces boulardii on Intestinal Mucosa
Authors
Jean-Paul Buts
Nadine De Keyser
Publication date
01-08-2006
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2006
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-005-9016-x

Other articles of this Issue 8/2006

Digestive Diseases and Sciences 8/2006 Go to the issue

Original Paper

Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled Study

Original Paper

Pathogenic Role of Endothelial Nitric Oxide Synthase (eNOS/NOS-III) in Cerulein-Induced Rat Acute Pancreatitis

Original Paper

Cross-Cultural Validation of Irritable Bowel Syndrome Quality of Life in Korea

Original Paper

Electroacupuncture Elicits Dual Effects: Stimulation of Delayed Gastric Emptying and Inhibition of Accelerated Colonic Transit Induced by Restraint Stress in Rats

Original Paper

The Efficacy of an Herbal Medicine, Carmint, on the Relief of Abdominal Pain and Bloating in Patients with Irritable Bowel Syndrome: A Pilot Study

Original Paper

Endoscopic Ultrasound Diagnosis of Pelvic Lipoma Causing Neurologic Symptoms
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits